MedTrace Logo

Duloxetine for the Treatment of Chronic Pelvic Pain

NCT01451606 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-09-26

Study results available
· View outcomes & findings →

Summary

This study is examining the effectiveness of duloxetine as a treatment for chronic pelvic pain in women. Duloxetine is FDA approved for the treatment of other pain conditions, including fibromyalgia and diabetic neuropathy.

Conditions

  • Pelvis Pain Chronic

Interventions

DRUG

Duloxetine

30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week

DRUG

Placebo

To serve as placebo for duloxetine. Administration schedule same as for active drug.

Sponsors & Collaborators

Principal Investigators

  • Joel Greenspan, Ph.D. · University Of Maryland Dental School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-11
Primary Completion
2015-11-04
Completion
2015-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01451606 on ClinicalTrials.gov